
<!DOCTYPE html>
<!-- saved from url=(0063)https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm -->
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>New-onset atrial fibrillation - Treatment algorithm | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="description" content="Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age and affects almost 5% of the population older than 69 years of age. Causes significant morbidity and mortality including palpitations, dyspnoea, angina, dizziness or syncope, and features of congesti...">
      <meta name="author" content="Arti N. Shah">
      <meta name="author" content="Bharat K. Kantharia">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="./3_management_treatment_algorithm_files/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="./3_management_treatment_algorithm_files/414393182248444" async=""></script><script async="" src="./3_management_treatment_algorithm_files/fbevents.js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/analytics.js"></script><script async="" src="./3_management_treatment_algorithm_files/get-loader.js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/insight.min.js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/uwt.js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/4896.js"></script><script type="text/javascript" async="" src="./3_management_treatment_algorithm_files/analytics.js"></script><script async="" src="./3_management_treatment_algorithm_files/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script>
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/3/treatment-algorithm">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/3/treatment-algorithm">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/3/treatment-algorithm">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/3/treatment-algorithm">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/3/treatment-algorithm">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/3/treatment-algorithm">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/3/treatment-algorithm">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/3/treatment-algorithm">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/3/treatment-algorithm">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/3/treatment-algorithm">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/3/treatment-algorithm">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/3/treatment-algorithm">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/3/treatment-algorithm">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/3/treatment-algorithm">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/3/treatment-algorithm">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/3/treatment-algorithm">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/3/treatment-algorithm">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <meta name="msvalidate.01" content="76FD53F39FDFB050A93D7925608BA016">
      <style type="text/css">._6772342E312E39_src-lib-Adapter-styles__centerStyle--2U8wI, ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M, ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio, ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         top: 50%;
         position: absolute;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         box-sizing: border-box;
         padding: 0;
         border-radius: 3px;
         position: fixed;
         display: block;
         visibility: visible;
         bottom: 0;
         background-color: #f3f3f3;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, -webkit-transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out, -webkit-transform 0.1s 0s ease-in-out;
         z-index: 99999;
         box-shadow: 0px 0px 5px 1px rgba(0, 0, 0, 0.18);
         overflow: hidden;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dragging--2uZno {
         transition: opacity 0.1s 0s linear;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__closed--eHbpJ {
         visibility: hidden;
         opacity: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__loading--1ewAG {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         position: relative;
         height: 35px;
         line-height: 35px;
         min-width: 165px;
         text-align: center;
         cursor: move;
         z-index: 11;
         overflow: hidden;
         font-family: Helvetica;
         font-weight: normal;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         cursor: ew-resize;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         left: 50%;
         height: 16px;
         width: 100px;
         margin-top: -8px;
         margin-left: -50px;
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 20px;
         height: 14px;
         width: 14px;
         border-radius: 8px;
         margin-top: -7px;
         display: none;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__dropdownPresence--18mrh {
         display: none;
         position: absolute;
         width: 100%;
         height: 100vh;
         }
         ._6772342E312E39_src-lib-Adapter-styles__showDropdown--242EQ {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj {
         padding: 10px 15px;
         display: block;
         cursor: pointer;
         text-decoration: none;
         text-align: left;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj:hover {
         background-color: #f5f5f5;
         }
         ._6772342E312E39_src-lib-Adapter-styles__selected--1z5-3 {
         color: #0684bd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM {
         position: relative;
         width: 160px;
         min-width: 165px;
         left: 5px;
         padding: 0;
         min-height: 30px;
         box-sizing: border-box;
         box-shadow: 0 0 4px 0 rgba(0, 0, 0, 0.2);
         background-color: #ffffff;
         border-style: solid;
         border-width: 0;
         border-top-width: 1px;
         border-bottom-width: 0px;
         border-color: #eeeeee;
         border-radius: 4px;
         font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;
         font-size: 14px;
         color: #2F2F2F;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__horizontal--1DydQ {
         display: inline-flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__clickable--G0zEI {
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__noborder--1ysDv {
         border: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 10px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Offline--3PnxB {
         display: block;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Busy--IDedL {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Available--2GLYE {
         display: block;
         background-color: #32ae31;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: none;
         position: absolute;
         width: 8px;
         height: 2px;
         border-radius: 1.5px;
         background-color: #ffffff;
         -webkit-transform-origin: 50% 50%;
         transform-origin: 50% 50%;
         -webkit-transform: translate(3px, 6px);
         transform: translate(3px, 6px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__statusIcon--2SoFd {
         display: inline-block;
         position: relative;
         margin-right: 5px;
         top: 2px;
         left: 0;
         margin-top: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         box-sizing: border-box;
         height: 20px;
         width: 20px;
         margin-top: -12px;
         border-radius: 3px;
         cursor: pointer;
         border-style: solid;
         border-width: 1px;
         border-color: transparent;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw:hover {
         border-color: #cccccc;
         }
         ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 40px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         position: absolute;
         box-sizing: border-box;
         left: 3px;
         bottom: 7px;
         width: 12px;
         height: 2px;
         border: 1px solid #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         height: 12px;
         bottom: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIconBar--2WYhn {
         width: 100%;
         height: 1px;
         background-color: #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR {
         position: relative;
         overflow: hidden;
         margin: 2px;
         width: 14px;
         height: 14px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child, ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         position: absolute;
         height: 2px;
         width: 100%;
         top: 6px;
         left: 0;
         background: #888888;
         border-radius: 1px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child {
         -webkit-transform: rotate(45deg);
         transform: rotate(45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         -webkit-transform: rotate(-45deg);
         transform: rotate(-45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__contentFrame--Z6dLx {
         display: block;
         border: none;
         width: 0;
         height: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.1s 0s ease-in-out, height 0.1s 0s ease-in-out;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__ringing--2c7d0 {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         -webkit-animation-duration: 2s;
         animation-duration: 2s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: infinite;
         animation-iteration-count: infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 33px;
         margin-left: -60px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 100px;
         margin-left: -100px;
         text-overflow: ellipsis;
         overflow: hidden;
         text-align: center;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__center--3fFya, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -50px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #5FB95C;
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX:hover {
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         margin-left: -80px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #FF8800;
         color: #FF8800;
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL:hover {
         color: #FF8800;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__detectNew--2RyZg {
         background: url("https://rc-hack-new.detect");
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         top: initial !important;
         width: 300px;
         border-top-right-radius: 0;
         border-bottom-right-radius: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg {
         width: 60px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         width: 35px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         opacity: 0 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__expandable--1dLZX {
         width: 140px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         line-height: initial;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         width: 12px;
         height: 12px;
         margin-top: -6px;
         z-index: 2;
         transition: .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         -webkit-transform: translate(2px, 5px);
         transform: translate(2px, 5px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         opacity: 0;
         transition: opacity .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         z-index: 2147483648;
         top: 7px;
         position: absolute;
         left: 30px;
         height: 22px;
         width: 22px;
         display: block;
         cursor: pointer;
         opacity: 1;
         transition: .3s;
         display: flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv ._6772342E312E39_src-lib-Adapter-styles__icon--2I9x4 {
         width: 22px;
         height: 22px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         left: 7px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.2s 0s ease-in-out, height 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOutIcon--oudoy img {
         position: absolute;
         top: 3px;
         left: 1px;
         width: 14px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         display: none;
         height: 30px;
         left: 0;
         position: fixed;
         top: 0;
         -webkit-transform: opacity 0.1s 0s linear;
         transform: opacity 0.1s 0s linear;
         z-index: 999999999;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         background-color: rgba(255, 255, 255, 0.95);
         box-sizing: border-box;
         border: 1px solid #cfcfcf;
         border-radius: 4px;
         font-size: 0px;
         height: 30px;
         white-space: nowrap;
         margin: 0 0 0 5px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 img {
         vertical-align: baseline !important;
         display: inline-block !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         margin: 0 5px 0 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #cfcfcf;
         top: calc(50% - 5px);
         left: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #FF8800;
         top: calc(50% - 5px);
         left: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         border-right: none;
         border-left: 5px solid #cfcfcf;
         left: initial;
         right: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         border-right: none;
         border-left: 5px solid #fff;
         left: initial;
         right: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU {
         height: 30px;
         width: 30px;
         margin: -1px 0 0 -1px;
         vertical-align: baseline;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: none;
         position: relative;
         vertical-align: top;
         cursor: pointer;
         font-size: 18px;
         height: 28px;
         width: 28px;
         line-height: 28px;
         text-align: center;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 {
         display: none;
         width: 1px;
         height: 19px;
         margin: 5px 0;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__hack--5AVJK {
         background: url("https://rc-hack-c2d.detect");
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg {
         position: absolute;
         top: 50%;
         left: 50%;
         -webkit-transform: translateX(-50%) translateY(-50%);
         transform: translateX(-50%) translateY(-50%);
         overflow: visible !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg > path {
         fill: #0684bd;
         stroke: #0684bd;
         }
      </style>
      <style type="text/css">add-meeting-button {
         line-height: 36px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__root--3CtVK {
         margin-left: 8px;
         position: relative;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q {
         min-width: 94px;
         white-space: nowrap;
         height: 26px;
         line-height: 26px;
         padding: 0;
         font-size: 11px;
         font-weight: 500;
         text-align: center;
         color: #0684bd;
         background: #fff;
         border-radius: 20px;
         border: 1px solid #9bcee5;
         font-family: Roboto, Helvetica, Arial, sans-serif;
         font-weight: 400;
         outline: none;
         cursor: pointer;
         transition: .3s;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q:hover {
         color: #fff;
         background-color: #9bcee5;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1 {
         color: #fff;
         background-color: #c7c7c7;
         border: 1px solid #c7c7c7;
         cursor: default;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1:hover {
         cursor: default;
         background-color: #c7c7c7;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__or--Hsdgj {
         float: left;
         margin-left: 10px;
         font-size: 12px;
         color: #0684bd;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__icon--r7sAL {
         left: 5px;
         top: 4px;
         width: 18px;
         height: 18px;
         position: absolute;
         background: #fff;
         border-radius: 100%;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__text--1nLnV {
         width: 100%;
         margin-left: 25px;
         padding-right: 6px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__meetingContainer--24va2 {
         display: flex;
         flex-grow: 100;
         align-items: center;
         }
      </style>
      <style type="text/css">#rc-meeting-popup-window {
         width: 100%;
         height: 100%;
         background-color: rgba(0, 0, 0, 0.3);
         display: flex;
         justify-content: center;
         align-items: center;
         line-height: normal;
         text-align: left;
         position: fixed;
         z-index: 2147483647;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__container--2qd2O {
         width: 470px;
         height: auto;
         display: flex;
         flex-direction: column;
         align-items: stretch;
         overflow: hidden;
         box-shadow: 0 24px 38px 3px rgba(0, 0, 0, 0.14), 0 9px 46px 8px rgba(0, 0, 0, 0.12), 0 11px 15px -7px rgba(0, 0, 0, 0.2);
         border-radius: 2px;
         position: relative;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA {
         position: relative;
         width: 100%;
         height: 30px;
         line-height: 30px;
         font-size: 12px;
         box-sizing: border-box;
         background: #ffffff;
         padding-left: 15px;
         padding-top: 10px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__recurringMeetingPrompt--3U97a {
         margin: 5px 22px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X {
         position: absolute;
         top: 13px;
         right: 15px;
         color: rgba(0, 0, 0, 0.54);
         fill: rgba(0, 0, 0, 0.54);
         width: 20px;
         height: 20px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X svg {
         width: 20px;
         height: 20px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__wrapper--3DttD {
         background-color: #ffffff;
         width: 100%;
         padding: 10px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settings--15yhX {
         border-radius: 3px;
         box-sizing: border-box;
         padding: 0 8px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryLabel--2n8iQ {
         margin: 10px 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryWrapper--2LA96 {
         border-radius: 3px;
         background-color: #F9F9F9;
         border: 1px solid #E2E2E2;
         padding: 9px 16px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settingLabel--ybCle {
         display: inline-block;
         width: 80px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF {
         line-height: 20px;
         margin: 7px 0;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF * {
         vertical-align: middle;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__video--1oJss {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__audio--2dr2m {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF input:first-of-type {
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__controls--1GgrW {
         margin: 10px 0 10px 10px;
         height: 30px;
         line-height: 30px;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__schedule--3SMpg {
         background: #4285f4;
         color: #fff;
         transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
         box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14), 0 3px 1px -2px rgba(0, 0, 0, 0.12), 0 1px 5px 0 rgba(0, 0, 0, 0.2);
         border: 0;
         border-radius: 3px;
         cursor: pointer;
         display: inline-block;
         font-weight: 500;
         outline: none;
         overflow: hidden;
         text-align: center;
         z-index: 0;
         font-size: 12px;
         line-height: 30px;
         height: 32px;
         min-width: 88px;
         position: absolute;
         right: 18px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA span {
         font-size: 16px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__password--3Ij_s {
         display: none;
         margin-left: 10px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__spinner--18fX2 {
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         ._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__path--2xqMm {
         stroke-dasharray: 187;
         stroke-dashoffset: 0;
         -webkit-transform-origin: center;
         transform-origin: center;
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
      </style>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 " style="">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-register" class="nav-item">
                        <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                     </li>
                     <li id="globalNav-login" class="nav-item">
                        <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            <!-- These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script><script type="text/javascript" id="">var meta=document.createElement("meta");meta.name="msvalidate.01";meta.content="76FD53F39FDFB050A93D7925608BA016";document.getElementsByTagName("head")[0].appendChild(meta);</script>
      <main id="tmp" class="container tmp treatment-table more-pops main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 3; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/3" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/3">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/3">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/3">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>New-onset atrial fibrillation</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/pdf/3.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 208px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 208px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="3_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="3_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/aetiology" id="Aetiology">Aetiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/case-history" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="3_diagnosis_recommedations.html" id="Recommendations">Recommendations</a></li>
                           <li><a href="3_diagnosis_history_and_exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="3_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/differentials" id="Differentials">Differentials</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/criteria" id="Criteria">Criteria</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/screening" id="Screening">Screening</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="3_management_recommendations.html" id="Recommendations">Recommendations</a></li>
                           <li><a href="3_management_treatment_algorithm.html" id="Treatment algorithm" class="active">Treatment algorithm</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/prevention" id="Prevention">Prevention</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/patient-discussions" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/monitoring" id="Monitoring">Monitoring</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/complications" id="Complications">Complications</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/prognosis" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/guidelines" id="Guidelines">Guidelines</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/images-and-videos" id="Images and videos">Images and videos</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/references" id="References">References</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/patient-leaflets" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/calculators" id="Calculators">Calculators</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/evidence" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/3/pdf/3.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Treatment algorithm</h2>
         <p class="w-75">Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">see disclaimer</a></p>
         <div class="card">
            <div class="card-block">
               <div class="container">
                  <div class="rowHead" id="presumptive">
                     <div class="col-md-12">
                        INITIAL
                     </div>
                  </div>
                  <div class="panel">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="patientGroup-0-0">
                           <span>haemodynamically unstable</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="tab_0_0_0" aria-controls="panel_0_0_0" aria-expanded="false">
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">direct current (DC) cardioversion</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_0" id="panel_0_0_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Used immediately if the patient is haemodynamically unstable with chest pain, shortness of breath, dizziness or syncope, hypotension, and rapid heart rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is performed under adequate short-acting general anaesthesia and involves delivery of an electrical shock synchronised with the intrinsic activity of the heart by sensing the R wave of the ECG (i.e., synchronised). The energy output for successful termination of new-onset AF varies from 200 J to a maximum of 400 J depending on the body size and the presence of other co-morbid conditions. Lower energy of 100 J may be used as the starting level when biphasic energy is used.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 For patients with haemodynamically unstable AF, initiation of anticoagulation should not delay DC cardioversion. It is reasonable to consider administering intravenous bolus of unfractionated heparin followed by infusion, or low molecular weight heparin or direct-acting oral anticoagulant and to continue this after cardioversion unless contraindicated.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <!-- /.panel-group -->
               </div>
            </div>
         </div>
         <div class="card">
            <div class="card-block">
               <div class="container">
                  <div class="rowHead" id="acute">
                     <div class="col-md-12">
                        ACUTE
                     </div>
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="patientGroup-1-0">
                           <span>haemodynamically stable with left atrial thrombus</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_0" aria-controls="nested-collapse_1_0_0" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 without heart failure
                                 </span>
                                 </span> 
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_0" id="nested-collapse_1_0_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium-channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, left ventricular dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_1" aria-controls="nested-collapse_1_0_1" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_1" id="nested-collapse_1_0_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR (target 2 to 3)</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. In selected patients, heparin plus warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion, and may be required for longer in some patients.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_2" aria-controls="nested-collapse_1_0_2" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion following 3 to 4 weeks of anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_2" id="nested-collapse_1_0_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioversion should only be attempted once the patient has been established on anticoagulation with a target INR of 2 to 3 for 3 to 4 weeks, and following a repeat transoesophageal echocardiogram to confirm left atrial thrombus.
                                 <span class="figureWrap">
                                 <span class="figure">
                                 <span class="figimage">
                                 <img class="img-fluid" alt="com.bmj.content.model.Caption@49997820" src="../images/3-6_default.jpg" aria-describedby="img-3-6_default.jpg" data-w="450">
                                 </span>
                                 <span class="figcaption">
                                 <span id="img-3-6_default.jpg">
                                 <i class="remove">[Figure caption and citation for the preceding image starts]: </i>
                                 <span class="caption">
                                 Transoesophageal echocardiogram showing left atrial appendage clot. LA=left atrium; LAA=left atrial appendage; LV=left ventricle.
                                 </span>
                                 <span class="source">From the collection of Dr Bharat Kantharia</span>
                                 <i class="remove"> [Citation ends].</i>
                                 </span>
                                 </span>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, a prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_3" aria-controls="nested-collapse_1_0_3" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with digoxin or amiodarone</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_3" id="nested-collapse_1_0_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_993a0c03-eacc-4f87-a2c9-6daa0fdb215e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">digoxin</a><span>: </span><span>0.75 to 1.5 mg orally as a loading dose given in divided doses on first day, followed by maintenance dose of 0.125 to 0.5 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Digoxin is the preferred drug for rate control in patients with AF and heart failure.
                                 <span class="reference"> 
                                 <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/123/10/e269.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/93/6/1262.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone has multiclass (I to IV) anti-arrhythmic properties. It is used for rate control only if digoxin is contraindicated.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_4" aria-controls="nested-collapse_1_0_4" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_4" id="nested-collapse_1_0_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR (target 2 to 3)</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. In selected patients, heparin plus warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion, and may be required for longer in some patients.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_0_5" aria-controls="nested-collapse_1_0_5" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacologic cardioversion following 3 to 4 weeks of anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_0_5" id="nested-collapse_1_0_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioversion should only be attempted once the patient has been established on anticoagulation with a target INR of 2 to 3 for 3 to 4 weeks and following a repeat transoesophageal echocardiogram to confirm left atrial thrombus.
                                 <span class="figureWrap">
                                 <span class="figure">
                                 <span class="figimage">
                                 <img class="img-fluid" alt="com.bmj.content.model.Caption@2a23055b" src="../images/3-6_default.jpg" aria-describedby="img-3-6_default.jpg" data-w="450">
                                 </span>
                                 <span class="figcaption">
                                 <span id="img-3-6_default.jpg">
                                 <i class="remove">[Figure caption and citation for the preceding image starts]: </i>
                                 <span class="caption">
                                 Transoesophageal echocardiogram showing left atrial appendage clot. LA=left atrium; LAA=left atrial appendage; LV=left ventricle.
                                 </span>
                                 <span class="source">From the collection of Dr Bharat Kantharia</span>
                                 <i class="remove"> [Citation ends].</i>
                                 </span>
                                 </span>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF. "Suggestive" evidence of efficacy pharmacological conversion (OR, 5.7; CI, 1.0 to 33.4).
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, a prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="patientGroup-1-1">
                           <span>haemodynamically stable without left atrial thrombus: symptom onset &lt;48 hours</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_0" aria-controls="nested-collapse_1_1_0" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1
                                 </span>
                                 </span> 
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_0" id="nested-collapse_1_1_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, LV dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_1" aria-controls="nested-collapse_1_1_1" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_1" id="nested-collapse_1_1_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3855ba0b-e42c-43a1-ba53-89daa70f3640_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">vernakalant</a><span>: </span><span>3 mg/kg intravenous infusion over 10 min initially, followed by 15 min of observation, followed by 2 mg/kg intravenous infusion over 10 min if necessary</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients with low thromboembolic risk presenting with new-onset AF within 48 hours can undergo immediate cardioversion without the need for anticoagulation.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has non-competitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Vernakalant, a sodium- and ultra-rapid potassium-channel blocker with atrial selective effects, has been recommended for approval by the European Medicines Agency for rapid cardioversion of recent-onset AF to sinus rhythm in adults (≤7 days for non-surgical patients; ≤3 days for surgical patients).
                                 <span class="reference">
                                    <a href="#referencePop54" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[54]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117
                                       <rc-c2d-number data-rc-number=":1518-1525">:1518-1525</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/cgi/content/full/117/12/1518
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18332267?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop55" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[55]</a> 
                                 <span class="citationText" aria-hidden="true">Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-659.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circep.ahajournals.org/content/2/6/652.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19948506?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop56" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[56]</a> 
                                 <span class="citationText" aria-hidden="true">Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21232669?tool=bestpractice.com
                                 </span>
                                 </span>
                                 Before its use, contraindications should be checked, the patient should be adequately hydrated, and ECG and haemodynamic monitoring should be used. The infusion can be followed by DC cardioversion if necessary. 
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_2" aria-controls="nested-collapse_1_1_2" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_2" id="nested-collapse_1_1_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, LV dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_3" aria-controls="nested-collapse_1_1_3" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion + heparin</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_3" id="nested-collapse_1_1_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous heparin (activated partial thromboplastin time [aPTT] of 45 to 60 seconds) or subcutaneous low molecular weight heparin should be started before cardioversion.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_4" aria-controls="nested-collapse_1_1_4" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_4" id="nested-collapse_1_1_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Once sinus rhythm is restored, warfarin should be added to heparin, and heparin continued until the warfarin levels are therapeutic (INR 2-3). In selected patients warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_5" aria-controls="nested-collapse_1_1_5" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with digoxin or amiodarone</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_5" id="nested-collapse_1_1_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_993a0c03-eacc-4f87-a2c9-6daa0fdb215e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">digoxin</a><span>: </span><span>0.75 to 1.5 mg orally as a loading dose given in divided doses on first day, followed by maintenance dose of 0.125 to 0.5 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients with heart failure are considered at high risk of thromboembolism. Additional risk factors may also be present, including age ≥75 years, structural heart disease, diabetes, hypertension, rheumatic heart disease, prosthetic heart valves, or history of prior thromboembolism, and left ventricular ejection fraction is ≤35%.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Digoxin is the preferred drug for rate control in patients with AF and heart failure.
                                 <span class="reference"> 
                                 <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/123/10/e269.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/93/6/1262.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone has multiclass (I to IV) anti-arrhythmic properties. It is used for rate control only if digoxin is contraindicated.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_6" aria-controls="nested-collapse_1_1_6" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion + heparin</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_6" id="nested-collapse_1_1_6" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous heparin (activated partial thromboplastin time [aPTT] of 45 to 60 seconds) or subcutaneous low molecular weight heparin should be started before cardioversion.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_1_7" aria-controls="nested-collapse_1_1_7" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_1_7" id="nested-collapse_1_1_7" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation with warfarin is required for patients at high risk for thromboembolism after sinus rhythm has been restored.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Once sinus rhythm is restored, warfarin should be added to heparin, and heparin continued until the warfarin levels are therapeutic (INR 2-3).
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 In selected patients warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="patientGroup-1-2">
                           <span>haemodynamically stable without left atrial thrombus: symptom onset ≥48 hours</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_0" aria-controls="nested-collapse_1_2_0" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1
                                 </span>
                                 </span> 
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_0" id="nested-collapse_1_2_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, LV dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_1" aria-controls="nested-collapse_1_2_1" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">heparin</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_1" id="nested-collapse_1_2_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Heparin should be started, and cardioversion should be delayed until the patient is established on heparin with a target activated partial thromboplastin time of 45 to 60 seconds.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_2" aria-controls="nested-collapse_1_2_2" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacologic cardioversion once heparin anticoagulation established</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_2" id="nested-collapse_1_2_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioversion may be carried out once heparin is established provided the transoesophageal echocardiogram is negative.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_3" aria-controls="nested-collapse_1_2_3" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">consideration of long-term aspirin post-cardioversion</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_3" id="nested-collapse_1_2_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_af8c930f-f3d3-4beb-9b1f-d11116cfedfc_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">aspirin</a><span>: </span><span>300 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Following successful cardioversion, heparin can be discontinued and aspirin alone considered for long-term prophylaxis if required.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The decision to administer aspirin for long-term therapy in these patients should be individualised and discussed with the patient, as no major consensus exists for those with a CHADS2 score of 1, or a CHA2DS2-VASc score of 1 due to sex risk (i.e., female patients).
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop10" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[10]</a> 
                                 <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65
                                       <rc-c2d-number data-rc-number=":1385-1394">:1385-1394</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25770314?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                                 <span class="citationText" aria-hidden="true">Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/25677422?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The American Heart Association guidelines include aspirin as an option, while National Institute for Health and Care Excellence and European Society of Cardiology guidelines do not recommend it.
                                 <span class="reference">
                                    <a href="#referencePop3" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[3]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18
                                       <rc-c2d-number data-rc-number=":1609-1678">:1609-1678</rc-c2d-number>
                                       .
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://eurheartj.oxfordjournals.org/content/37/38/2893
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/27567465?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop10" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[10]</a> 
                                 <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_4" aria-controls="nested-collapse_1_2_4" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_4" id="nested-collapse_1_2_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, LV dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_5" aria-controls="nested-collapse_1_2_5" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_5" id="nested-collapse_1_2_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR (target 2 to 3)</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. In selected patients, heparin plus warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_6" aria-controls="nested-collapse_1_2_6" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 without heart failure: CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion following 3 to 4 weeks of anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_6" id="nested-collapse_1_2_6" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioversion should only be attempted once the patient has been established on anticoagulation with a target INR of 2 to 3 for 3 to 4 weeks.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, a prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_7" aria-controls="nested-collapse_1_2_7" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with digoxin or amiodarone</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_7" id="nested-collapse_1_2_7" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_993a0c03-eacc-4f87-a2c9-6daa0fdb215e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">digoxin</a><span>: </span><span>0.75 to 1.5 mg orally as a loading dose given in divided doses on first day, followed by maintenance dose of 0.125 to 0.5 mg once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Secondary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients with heart failure are considered at high risk of thromboembolism. Additional risk factors may also be present, including age ≥75 years, structural heart disease, diabetes, hypertension, rheumatic heart disease, prosthetic heart valves, or history of prior thromboembolism, and left ventricular ejection fraction is ≤35%.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Digoxin is the preferred drug for rate control in patients with AF and heart failure.
                                 <span class="reference"> 
                                 <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                                 <span class="citationText" aria-hidden="true">Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/123/10/e269.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/93/6/1262.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone has multiclass (I to IV) anti-arrhythmic properties. It is used for rate control only if digoxin is contraindicated.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_8" aria-controls="nested-collapse_1_2_8" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_8" id="nested-collapse_1_2_8" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR (target 2 to 3)</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. In selected patients, heparin plus warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_2_9" aria-controls="nested-collapse_1_2_9" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 with heart failure                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion following 3 to 4 weeks of anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_2_9" id="nested-collapse_1_2_9" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Cardioversion should only be attempted once the patient has been established on anticoagulation with a target INR of 2 to 3 for 3 to 4 weeks.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, a prolonged observation period is recommended in patients who have received ibutilide.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <div class="panel bg-line">
                     <div class="panel-heading">
                        <h3>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" id="patientGroup-1-3">
                           <span>haemodynamically stable without left atrial thrombus: asymptomatic</span>
                           <span class="hidden-sm-down">
                           <span class="msg">VIEW ALL</span>
                           <span class="material-icons" role="button"><span></span><span></span></span>
                           </span>
                           </a>
                        </h3>
                     </div>
                     <!--/.panel-heading -->
                     <div class="panel-body">
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_0" aria-controls="nested-collapse_1_3_0" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 CHA2DS2-VASc score 0-1
                                 </span>
                                 </span> 
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">observation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_0" id="nested-collapse_1_3_0" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Most cases of new-onset AF revert to sinus rhythm spontaneously. Cases that revert spontaneously usually do so in the first 24 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/93/6/1262.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients should be observed to see whether AF resolves spontaneously.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_1" aria-controls="nested-collapse_1_3_1" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 2nd line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_1" id="nested-collapse_1_3_1" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If AF does not resolve spontaneously, rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, left ventricular dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_2" aria-controls="nested-collapse_1_3_2" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 CHA2DS2-VASc score 0-1                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_2" id="nested-collapse_1_3_2" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If AF does not resolve spontaneously, cardioversion may be attempted without the need for anticoagulation.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_3" aria-controls="nested-collapse_1_3_3" aria-expanded="false">
                                 <span class="title-01">
                                 <span>  
                                 CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 1st line
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">anticoagulation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_3" id="nested-collapse_1_3_3" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>see local protocol for dosing guidelines, maintain activated partial thromboplastin time (aPTT) at 45-60 seconds</span>
                                    </p>
                                    <p class="small-or">or</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously every 12 hours</span>
                                    </p>
                                    <p class="and-or">-- AND --</p>
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5-10 mg orally once daily initially, adjust dose according to INR (target 2 to 3)</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>2.5 to 5 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>60 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients with higher thromboembolic risk require immediate anticoagulation.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. In selected patients, heparin plus warfarin may be replaced with a direct oral anticoagulant (DOAC) such as rivaroxaban, apixaban, edoxaban, or dabigatran. DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency.
                                 <span class="reference"> 
                                 <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                                 <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                                 <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Anticoagulation is continued for at least 4 weeks after cardioversion.
                                 <span class="reference">
                                    <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                                    <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                       http://content.onlinejacc.org/article.aspx?articleid
                                       <rc-c2d-number data-rc-number="=1854231
                                          ">=1854231</rc-c2d-number>
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_4" aria-controls="nested-collapse_1_3_4" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Plus
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">observation</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_4" id="nested-collapse_1_3_4" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Most cases of new-onset AF revert to sinus rhythm spontaneously. Cases that revert spontaneously usually do so in the first 24 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                                 <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://circ.ahajournals.org/content/93/6/1262.long
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Patients should be observed to see whether AF resolves spontaneously.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_5" aria-controls="nested-collapse_1_3_5" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">rate control with beta-blockers and/or calcium-channel blockers (CCBs)</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_5" id="nested-collapse_1_3_5" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0ec5673f-33cd-453a-a32d-d93b3919fe0f_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">esmolol</a><span>: </span><span>500 micrograms/kg intravenously as a loading dose, followed by 50 micrograms/kg/min infusion for 4 minutes, if no response after 5 minutes, repeat loading dose and increase infusion, consult specialist for further guidance on dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_d4b268c9-53e2-4caa-b5d4-36b5d1728141_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">metoprolol</a><span>: </span><span>2.5 to 5 mg intravenous bolus initially, may repeat every 5 minutes to a total of 3 doses; 25-200 mg orally (regular-release) twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_0530d633-bf69-4255-9831-68b8e56fb430_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propranolol</a><span>: </span><span>1 mg intravenously initially, may repeat every 2 minutes to a total of 3 doses; 10-40 mg orally (immediate-release) three to four times daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">atenolol</a><span>: </span><span>25-100 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_ed67ccf3-8ae2-4a3d-bc49-98304e550eb1_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">nadolol</a><span>: </span><span>10-240 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">bisoprolol</a><span>: </span><span>2.5 to 10 mg orally once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">carvedilol</a><span>: </span><span>3.125 to 25 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_7508539a-5d2a-4eab-ab36-fccb0194a2fe_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">diltiazem</a><span>: </span><span>0.25 mg/kg intravenous bolus initially, may give a second bolus of 0.35 mg/kg after 15 minutes if necessary, followed by 5-15 mg/hour infusion; 120-360 mg/day orally (regular-release) given in 3-4 divided doses</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b705ae48-b250-4f5e-af99-a9a1ab9c9dca_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">verapamil</a><span>: </span><span>5-10 mg intravenous bolus initially, may give a second bolus of 10 mg after 30 minutes if necessary, followed by a 0.005 mg/kg/minute infusion; 240-320 mg/day orally (regular-release) given in 3-4 divided doses; 180-480 mg orally (extended-release) once daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 <span class="inlineCalc">
                                 <span class="web-link-wrap">
                                 <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                                 Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                                 </a>
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If AF does not resolve spontaneously, rate-control therapy is required until cardioversion is successful.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers and CCBs slow AV nodal conduction of cardiac impulses and subsequently reduce ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Intravenous administration of beta-blockers or calcium channel blockers may be necessary for rapid control of ventricular rate. Furthermore, in an event of haemodynamic adverse effects, the infusion may be discontinued promptly.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Beta-blockers are particularly useful when new-onset AF is associated with an acute MI or angina, and when new-onset AF is precipitated after exercise.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Esmolol is useful in patients at risk of complications from beta-blockade, particularly those with reactive airway disease, left ventricular dysfunction, and/or peripheral vascular disease.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 CCBs are preferred in patients with chronic lung disease where bronchospasm may occur with beta-blockers.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Both groups of medications may cause severe bradycardia, heart block, asystole, heart failure, or hypotension.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If rate control is inadequate with monotherapy, a combination of a beta-blocker and CCB may be used.
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                        <section class="panel-group">
                           <div class="panel-header">
                              <p class="panel-title"> 
                                 <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" role="tab header" id="nested-collapse_1_3_6" aria-controls="nested-collapse_1_3_6" aria-expanded="false">
                                 <span class="title-01 noShow">
                                 <span>  
                                 CHA2DS2-VASc score ≥2                                                                                                                                                              
                                 </span>
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="titles-wrap col-md-12">
                                 <span class="title-02">
                                 <span class="title-03 col-md-1">
                                 Adjunct
                                 <span class="noShow">&nbsp;–&nbsp;</span>
                                 </span>
                                 <span class="title-04">
                                 <span class="material-icons"><span></span><span></span></span>
                                 <span class="txtwrap">electrical or pharmacological cardioversion</span>
                                 </span>
                                 </span>
                                 </span>
                                 </a>
                              </p>
                           </div>
                           <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="nested-collapse_1_3_6" id="nested-collapse_1_3_6" aria-expanded="false">
                              <!--  ADJUNCT/PLUS DISCLAIMER -->
                              <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                              <div class="treatment-wrap">
                                 <!-- display regimens -->
                                 <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                 <h4>Primary options</h4>
                                 <div class="treatment-box">
                                    <p>
                                       <span>direct current cardioversion</span><span></span><span></span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_18dde044-d579-4f4b-9388-9214655623a5_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">flecainide</a><span>: </span><span>200-300 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">propafenone</a><span>: </span><span>600 mg orally as a single dose</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_b0ed770b-3497-4dd2-919e-f9051080edd3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">amiodarone</a><span>: </span><span>150 mg intravenously initially, followed by 0.5 to 1 mg/min infusion for 24-48 hours</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_99bb002a-203f-41b7-9393-7a1af344bab0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dronedarone</a><span>: </span><span>400 mg orally twice daily</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                                 <p class="small-or">OR</p>
                                 <div class="treatment-box">
                                    <p>
                                       <a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#drugDbPop_235f34a0-d02e-49b6-9ba3-14ef1946d518_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">ibutilide</a><span>: </span><span>0.01 mg/kg (maximum 1 mg/dose) intravenously initially, may repeat 10 minutes after initial dose if no response</span>
                                    </p>
                                 </div>
                                 <!--/.treatment-box-->
                              </div>
                              <!--/.treatment-wrap-->
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 If AF does not resolve spontaneously, cardioversion should only be attempted once the patient has been established on anticoagulation with a target INR of 2 to 3 for 3 to 4 weeks.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 DC cardioversion is fast, safe, and efficient.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class IC agents (flecainide, propafenone) have a higher mortality in patients with CAD and are contraindicated in patients with CAD and cardiac dysfunction. AF may convert to atrial flutter that may conduct with rapid ventricular rate.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Flecainide has strong evidence of efficacy for pharmacological conversion (odds ratio [OR], 24.7; CI, 9.0 to 68.3). High conversion rate of about 70% at 3 hours after treatment and up to 90% at 8 hours.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Propafenone also has strong evidence of efficacy for pharmacological conversion (OR, 4.6; CI, 2.6 to 8.2). High conversion rates of up to 76% at 8 hours after treatment.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents in conversion to sinus rhythm.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Amiodarone provides additional benefit of improved rate control in patients with new-onset AF.
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Dronedarone is a multichannel blocker and has noncompetitive anti-adrenergic activity.
                                 <span class="reference"> 
                                 <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                                 <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                                 <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                                 </span>
                                 </span>
                                 <span class="reference"> 
                                 <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                                 <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                                 </span>
                                 </span>
                                 It is less effective than amiodarone but has fewer side effects. Although not used primarily for cardioversion, it may be used for maintenance of cardioversion after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II or III heart failure with a recent (within the previous 4 weeks) decompensation requiring hospitalisation or referral to a specialised heart failure clinic, and in patients with permanent AF.
                                 <span class="reference"> 
                                 <a href="#referencePop68" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[68]</a> 
                                 <span class="citationText" aria-hidden="true">sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
                                 </span>
                                 </span>
                                 <span class="reference">
                                    <a href="#referencePop69" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[69]</a> 
                                    <span class="citationText" aria-hidden="true">
                                       Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358
                                       <rc-c2d-number data-rc-number=":2678-2687 ">:2678-2687 </rc-c2d-number>
                                       (erratum in: N Engl J Med. 2010;363:1384).
                                    </span>
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.nejm.org/doi/full/10.1056/NEJMoa0800456#t=article
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/18565860?tool=bestpractice.com
                                    </span>
                                 </span>
                              </p>
                              <p class="w-75">
                                 <!-- col-md-9 -->
                                 Ibutilide prolongs repolarisation of the atrial tissue by enhancing the slow inward depolarising Na+ current in the plateau phase of repolarisation. Up to 70% of all conversions occur within 20 minutes of infusion. It has strong evidence of efficacy for pharmacological conversion (OR, 29.1; CI, 9.8 to 86.1). Conversion rates are between 33% and 45% within the first 70 minutes. Because the half-life of ibutilide is 3 to 6 hours, prolonged observation period is recommended in patients who have received ibutilide.
                                 <span class="reference"> 
                                 <a href="#referencePop67" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[67]</a> 
                                 <span class="citationText" aria-hidden="true">Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.</span> 
                                 <span class="citationFullTextUrl" aria-hidden="true">
                                 http://www.jfponline.com/Pages.asp?AID=2639
                                 </span>
                                 <span class="referenceUniqueId" aria-hidden="true">
                                 http://www.ncbi.nlm.nih.gov/pubmed/11093570?tool=bestpractice.com
                                 </span>
                                 </span>
                              </p>
                           </div>
                           <!--/.panel-body -->
                        </section>
                     </div>
                     <!--/.panel-body -->
                  </div>
                  <!-- /.panel-group -->
               </div>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
         <script type="text/javascript">//<![CDATA[
            var drugDatabases = ["AHFS","BNF","BNFC","MARTINDALE","MICROMEDEX"];
            var drugMappings = {"ed67ccf3-8ae2-4a3d-bc49-98304e550eb1":{"AHFS":"382666","BNF":"787136372","MARTINDALE":"6315-l"},"99bb002a-203f-41b7-9393-7a1af344bab0":{"AHFS":"309025","BNF":"669785989","MARTINDALE":"5516-y"},"3855ba0b-e42c-43a1-ba53-89daa70f3640":{"MARTINDALE":"21273-w"},"b705ae48-b250-4f5e-af99-a9a1ab9c9dca":{"BNFC":"111880283","AHFS":"384030","BNF":"111880283","MARTINDALE":"7794-v"},"235f34a0-d02e-49b6-9ba3-14ef1946d518":{"AHFS":"396017","MARTINDALE":"13799-k"},"e99c3484-9b46-43a0-9f8b-b2f23fcdc2ab":{"AHFS":"398002","BNF":"528691203","MARTINDALE":"13177-w"},"4866ce04-4d68-4b50-83f4-66283ea52c07":{"BNFC":"347445885","AHFS":"382826","BNF":"347445885","MARTINDALE":"11401-s"},"ed0b35d8-aa5b-479b-94e5-1ee8ca57ec47":{"BNFC":"811991159","AHFS":"384031","BNF":"811991159","MARTINDALE":"6304-s"},"0f8c4ada-cd84-4c04-8860-01a81e07c1f9":{"AHFS":"312005","BNF":"758974083","MARTINDALE":"22005-r"},"3984222a-c42a-4f8a-bff1-f99645ade85d":{"BNFC":"190424995","AHFS":"393016","BNF":"190424995","MARTINDALE":"13424-s"},"4b33f194-29da-4239-aae9-c1746e2bda94":{"AHFS":"315041","BNF":"142886536","MARTINDALE":"25433-t"},"18dde044-d579-4f4b-9388-9214655623a5":{"BNFC":"264345609","AHFS":"386009","BNF":"264345609","MARTINDALE":"12753-a"},"7508539a-5d2a-4eab-ab36-fccb0194a2fe":{"BNFC":"873608533","AHFS":"384027","BNF":"873608533","MARTINDALE":"9225-e"},"7a2f8cf6-5b94-4fc8-b62d-07d6cfc8444c":{"BNFC":"563610075","AHFS":"397042","BNF":"563610075","MARTINDALE":"18917-n"},"aff9d94e-1579-4f56-acb7-73775d12d818":{"AHFS":"313017","BNF":"379487049","MARTINDALE":"24489-b"},"0ec5673f-33cd-453a-a32d-d93b3919fe0f":{"BNFC":"964697517","AHFS":"387013","BNF":"964697517","MARTINDALE":"16636-f"},"b0ed770b-3497-4dd2-919e-f9051080edd3":{"BNFC":"675219041","AHFS":"387009","BNF":"675219041","MARTINDALE":"20490-e"},"1f043ef5-6686-4b38-a018-9dea67de1e36":{"BNFC":"107604022","AHFS":"382277","BNF":"107604022","MARTINDALE":"21515-l"},"af8c930f-f3d3-4beb-9b1f-d11116cfedfc":{"BNFC":"456850132","AHFS":"382878","BNF":"456850132","MARTINDALE":"2601-s"},"09fb6bfc-ec5f-49e2-9858-d7c7d0ab44f4":{"AHFS":"393024","BNF":"281805035","MARTINDALE":"18615-w"},"6402d40a-aa86-4def-a6af-9d56b0e8ef3e":{"AHFS":"311009","BNF":"860832161","MARTINDALE":"20786-b"},"0530d633-bf69-4255-9831-68b8e56fb430":{"BNFC":"202997782","AHFS":"382607","BNF":"202997782","MARTINDALE":"6301-g"},"d4b268c9-53e2-4caa-b5d4-36b5d1728141":{"BNFC":"671210145","AHFS":"382864","BNF":"671210145","MARTINDALE":"14830-p"},"993a0c03-eacc-4f87-a2c9-6daa0fdb215e":{"BNFC":"154218357","AHFS":"382301","BNF":"154218357","MARTINDALE":"5801-a"}};
            //]]>
         </script>
      </main>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn">
                     <small>
                        ISSN
                        <rc-c2d-number data-rc-number=" 2515-9615"> 2515-9615</rc-c2d-number>
                     </small>
                  </p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: New-onset atrial fibrillation - Treatment algorithm | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="New-onset atrial fibrillation - Treatment algorithm | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p>
                                       <b>Phone:</b> 
                                       <rc-c2d-number data-rc-number="+44 (0) 207 111 1105">+44 (0) 207 111 1105</rc-c2d-number>
                                    </p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/3/treatment-algorithm#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 3;
           var topicLang = "en-gb";
           var topicTitle = "New-onset atrial fibrillation";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script src="../js/adsct.js" type="text/javascript"></script><script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/3\/treatment-algorithm",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <rc-c2d-menu class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF">
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05">
            <img class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU" src="data:image/png;base64,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">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="Call with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 26">
                  <path fill="#0083BF" fill-rule="evenodd" stroke="#0684BD" stroke-width=".9" d="M6.656 17.651C.942 10.547.28 4.627 2.545 2.607c.592-.522 2.16-1.323 2.892-1.427.801-.14 1.602.243 2.02 1.01.802 1.636 1.777 3.238 2.788 4.805.452.697.348 1.567-.244 2.16-.349.348-.767.557-1.15.765a3.18 3.18 0 0 0-.801.523s-.105.104-.105.313c-.035.453.035 1.707 2.02 4.214 2.16 2.647 3.45 2.82 3.798 2.82.14 0 .244-.034.244-.034.244-.21.453-.453.662-.697.314-.348.593-.696 1.01-.975.697-.452 1.638-.348 2.16.21 1.325 1.323 2.753 2.576 4.112 3.76.662.557.906 1.428.557 2.16-.244.66-1.359 2.02-2.02 2.541-.558.488-1.324.697-2.195.697-3.345 0-7.7-2.925-11.637-7.8z"></path>
               </svg>
            </div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v"></div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="SMS with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 22 21">
                  <path fill="#0684BD" fill-rule="nonzero" d="M10.944.014C4.91.014.007 4.068.007 9.316c0 2.86 1.54 5.626 4.085 7.417-.094.534-.377 1.257-1.162 2.64l-.692 1.131h1.383a6.976 6.976 0 0 0 4.84-1.917c.817.157 1.634.252 2.483.252 6.034 0 10.936-4.275 10.936-9.523 0-5.28-4.902-9.302-10.936-9.302z"></path>
               </svg>
            </div>
         </div>
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO"></div>
         </div>
      </rc-c2d-menu>
      <script src="../js/saved_resource.js" type="text/javascript"></script>
   </body>
</html>
